Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance.

[1]  V. Calvez,et al.  Caution is needed in interpreting HIV transmission chains by ultradeep sequencing , 2019, AIDS.

[2]  Kimberly Smith,et al.  Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. , 2019, The Lancet. Infectious diseases.

[3]  P. Ghys,et al.  Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. , 2019, The Lancet. Infectious diseases.

[4]  C. Fraser,et al.  Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  N. Markowitz,et al.  Hematopoietic Stem and Progenitor Cells Are a Distinct HIV Reservoir that Contributes to Persistent Viremia in Suppressed Patients. , 2018, Cell reports.

[6]  T. F. Rinke de Wit,et al.  HIV drug resistance in low-income and middle-income countries. , 2018, The lancet. HIV.

[7]  M. Wainberg,et al.  The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors , 2018, The Journal of infectious diseases.

[8]  C. Boucher,et al.  HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy , 2018, The Journal of infectious diseases.

[9]  S. Lewin,et al.  Barriers and strategies to achieve a cure for HIV. , 2018, The lancet. HIV.

[10]  M. Nussenzweig,et al.  Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation , 2018, Nature Medicine.

[11]  Ingrid A. Beck,et al.  Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort , 2018, PLoS medicine.

[12]  Jeffrey M. Gerold,et al.  Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane , 2018, Proceedings of the National Academy of Sciences.

[13]  D. Lewis,et al.  HIV Persistence in Adipose Tissue Reservoirs , 2018, Current HIV/AIDS Reports.

[14]  H. Günthard,et al.  Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics , 2018, PLoS pathogens.

[15]  J. Benito,et al.  Peripheral T follicular helper Cells Make a Difference in HIV Reservoir Size between Elite Controllers and Patients on Successful cART , 2017, Scientific Reports.

[16]  D. Richman,et al.  Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc , 2017, Journal of Virology.

[17]  D. Podzamczer,et al.  Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial , 2017, The Lancet.

[18]  K. White,et al.  Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial , 2017, The Lancet.

[19]  R. Siliciano,et al.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study , 2017, PLoS medicine.

[20]  E. Boritz,et al.  Identification of Genetically Intact HIV-1 Proviruses in Specific CD4+ T Cells from Effectively Treated Participants. , 2017, Cell reports.

[21]  J. Mellors,et al.  No evidence of HIV replication in children on antiretroviral therapy. , 2017, The Journal of clinical investigation.

[22]  V. Calvez,et al.  Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors , 2017, mBio.

[23]  Ellen R. Forsyth,et al.  Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir , 2017, mBio.

[24]  S. Little,et al.  No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men , 2017, Journal of Virology.

[25]  J. Mellors,et al.  Ongoing HIV Replication During ART Reconsidered , 2017, Open forum infectious diseases.

[26]  E. Rosenberg,et al.  Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells , 2017, The Journal of clinical investigation.

[27]  P. Harrigan,et al.  Emergent drug resistance with integrase strand transfer inhibitor-based regimens , 2017, AIDS.

[28]  Alison L. Hill,et al.  Re-evaluating evolution in the HIV reservoir , 2017, Nature.

[29]  M. Wainberg,et al.  HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters , 2017, The Journal of antimicrobial chemotherapy.

[30]  Jing Leng,et al.  The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration , 2017, mBio.

[31]  Daniel I. S. Rosenbloom,et al.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics , 2017, The Journal of experimental medicine.

[32]  K. White,et al.  Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. , 2017, The lancet. HIV.

[33]  S. Hughes,et al.  Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir , 2017, PLoS pathogens.

[34]  C. Petropoulos,et al.  Epistasis and Pleiotropy Affect the Modularity of the Genotype–Phenotype Map of Cross-Resistance in HIV-1 , 2016, Molecular biology and evolution.

[35]  D. Pillay,et al.  Genome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug Resistance , 2016, bioRxiv.

[36]  S. Hughes,et al.  Multiple Origins of Virus Persistence during Natural Control of HIV Infection , 2016, Cell.

[37]  O. Pybus,et al.  HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer , 2016, Journal of Virology.

[38]  J. Ananworanich,et al.  HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART , 2016, EBioMedicine.

[39]  R. Levy,et al.  Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease , 2016, bioRxiv.

[40]  Jan Albert,et al.  Establishment and stability of the latent HIV-1 DNA reservoir , 2016, bioRxiv.

[41]  Ellen R. Forsyth,et al.  Quantitation of Productively Infected Monocytes and Macrophages of Simian Immunodeficiency Virus-Infected Macaques , 2016, Journal of Virology.

[42]  Trevor Bedford,et al.  Persistent HIV-1 replication maintains the tissue reservoir during therapy , 2015, Nature.

[43]  D. Podzamczer,et al.  Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial , 2015, Journal of acquired immune deficiency syndromes.

[44]  O. Gascuel,et al.  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK , 2015, AIDS.

[45]  D. Pillay,et al.  Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. , 2015, The lancet. HIV.

[47]  Huldrych F. Günthard,et al.  Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds , 2015, PLoS pathogens.

[48]  P. Lemey,et al.  Longitudinal Genetic Characterization Reveals That Cell Proliferation Maintains a Persistent HIV Type 1 DNA Pool During Effective HIV Therapy. , 2015, The Journal of infectious diseases.

[49]  M. Wainberg,et al.  Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase , 2014, Journal of Virology.

[50]  L. Picker,et al.  A B cell follicle sanctuary permits persistent productive SIV infection in elite controllers , 2014, Nature Medicine.

[51]  M. Poljak,et al.  Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity , 2014, Retrovirology.

[52]  D. Fuchs,et al.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation , 2014, AIDS.

[53]  P. Massip,et al.  Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy. , 2014, The Journal of antimicrobial chemotherapy.

[54]  J. Mellors,et al.  Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[55]  Alan S Perelson,et al.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues , 2014, Proceedings of the National Academy of Sciences.

[56]  H. Günthard,et al.  Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  E. Rosenberg,et al.  HIV-1 persistence in CD4+ T cells with stem cell-like properties , 2014, Nature Medicine.

[58]  P. Lemey,et al.  The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time , 2013, Proceedings of the National Academy of Sciences.

[59]  J. Gatell,et al.  Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[60]  M. Hughes,et al.  Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  Clare Brennan,et al.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.

[62]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[63]  M. Markowitz,et al.  Absence of HIV-1 Evolution in the Gut-Associated Lymphoid Tissue from Patients on Combination Antiviral Therapy Initiated during Primary Infection , 2012, PLoS pathogens.

[64]  M. Wainberg,et al.  Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir , 2011, Journal of Virology.

[65]  Sebastian Bonhoeffer,et al.  A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase , 2011, Nature Genetics.

[66]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[67]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[68]  P. Cahn,et al.  The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART , 2007, AIDS.

[69]  G Achaz,et al.  A robust measure of HIV-1 population turnover within chronically infected individuals. , 2004, Molecular biology and evolution.

[70]  D. Nickle,et al.  Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy , 2002, Journal of Virology.

[71]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[73]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[74]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[75]  W. Heneine,et al.  Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network. , 2017, Virus evolution.